SamanthaMaryJaglowskiMDMPH

PubMed

• Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
  Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, John C Byrd, Julio C Chavez, Matthew S Davids, Jamie P Dela Cruz, Mark R Dowling, Caitlyn Duffy, Carr...> ;Journal of Clinical Oncology. 2024 Mar 29
• 2 citations
  A phase 2 trial of CD24Fc for prevention of graft-versus-host disease.
  John Magenau, Samantha Jaglowski, Joseph Uberti, Sherif S Farag, Mary Mansour Riwes, Attaphol Pawarode, Sarah Anand, Monalisa Ghosh, John Maciejewski, Thomas Braun, Ma...> ;Blood. 2024 Jan 4
• 3 citations
  Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor.
  Zachary D Crees, Michael P Rettig, Asad Bashey, Steven M Devine, Samantha Jaglowski, Fei Wan, Amy Zhou, Melinda Harding, Abi Vainstein-Haras, Ella Sorani, Irit Gliko-K...> ;Blood Advances. 2023 Sep 26
• 13 citations
  A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.
  Geoffrey Shouse, Andy Kaempf, Max J Gordon, Andy Artz, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven M Bair, Agrima Mian, Lindsey A Fitzgerald, Amneet Bajwa, ...> ;Blood Advances. 2023 Jul 25
• Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safet...
  Vincent T Ho, Thomas R Klumpp, Wayne H Liang, Matt Prestegaard, Mitchell Horwitz, Betty K Hamilton, Kristin Page, Samantha Jaglowski, John Huber, Charles Martinez, Vin...> ;Transplantation and Cellular Therapy. 2023 Sep 1
• Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracil.
  Ashley N Gray, Christina Avila, Catherine G Chung, Lucia Seminario-Vidal, Alice Mims, Brittany Dulmage, Karilyn Larkin, Hannah Choe, Samantha Jaglowski, Sumithira Vasu...> ;JAAD Case Reports. 2023 Jun 1
• 1 citations
  Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
  Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S L Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, ...> ;Transplantation and Cellular Therapy. 2023 Jun 1
• 4 citations
  A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
  Walter Hanel, Polina Shindiapina, David A Bond, Yazeed Sawalha, Narendranath Epperla, Timothy Voorhees, Rina Li Welkie, Ying Huang, Gregory K Behbehani, Xiaoli Zhang, ...> ;Cancers. 2023 Feb 24
• Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine.
  Sonia Himed, Catherine Chung, Brittany Dulmage, Samantha Jaglowski, David Bond, Kami Maddocks, Benjamin H Kaffenberger> ;Journal of the European Academy of Dermatology and Venereology. 2023 Jul 1
• Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.
  Muhammad Salman Faisal, Walter Hanel, Timothy Voorhees, Rui Li, Ying Huang, Abdullah Khan, David Bond, Yazeed Sawalha, John Reneau, Lapo Alinari, Robert Baiocchi, Beth...> ;Cancer Medicine. 2023 Apr 1
• 14 citations
  Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
  Mahmoud Elsawy, Julio C Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D Rudzki, Saurabh Dahiya, Kath...> ;Blood. 2022 Nov 24
• Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.
  Sanghee Hong, Jing Zhao, Shu Wang, Han Wang, Ji-Hyun Lee, Nosha Farhadfar, Joseph P McGuirk, Bipin N Savani, Hashmi K Shahrukh, Patrick Stiff, Nandita Khera, Theresa H...> ;Transplantation and Cellular Therapy. 2023 Mar 1
• 1 citations
  Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
  Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Don M Benson, Sumithira Vasu, Samantha Jaglowski, Alice Mims, Hannah Choe, Karilyn Larkin, Jonathan E Bram...> ;Cancers. 2022 Nov 14
• 3 citations
  Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem.
  Jane Koo, Jeffrey J Auletta, David M Hartley, John Huber, Samantha Jaglowski, Malika Kapadia, Katilyn Kusnier, Leslie Lehmann, Joseph Maakaron, Kasiani C Myers, Ahna P...> ;Transplantation and Cellular Therapy. 2022 Nov 1
• EXABS-211-CT Building Your CAR-T Program.
  Samantha M Jaglowski, Marcos de Lima> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 1 citations
  Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
  Ulrich Jaeger, Constantine S Tam, Peter Borchmann, Joseph P McGuirk, Marianne Johansen, Edmund K Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R Foley, Ja...> ;Blood Advances. 2022 Aug 23
• 3 citations
  Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
  Audrey M Sigmund, Ying Huang, Amy S Ruppert, Kami Maddocks, Kerry A Rogers, Samantha Jaglowski, Seema A Bhat, Adam S Kittai, Michael R Grever, John C Byrd, Jennifer A ...> ;Leukemia. 2022 Aug 1
• 30 citations
  Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
  Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo, Lorenzo Iovino, Ana Alarcon Tomas, Craig Sauter, Miguel-Angel Perales, Nirav N Shah, Utkarsh H...> ;Haematologica. 2023 Jan 1
• A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
  David A Bond, Ying Huang, Beth A Christian, Samantha Jaglowski, Don Benson, Lapo Alinari, Robert A Baiocchi, Jonathon B Cohen, Kristie A Blum, Kami J Maddocks> ;Leukemia & Lymphoma. 2022 Jul 1
• 70 citations
  Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
  Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A Mc...> ;Journal of Clinical Oncology. 2023 Jan 20
• 3 citations
  Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
  Audrey M Sigmund, Nathan Denlinger, Ying Huang, David Bond, Timothy Voorhees, Amneet Bajwa, Patrick Elder, Jonathan E Brammer, Ayman Saad, Sam Penza, Sumithira Vasu, M...> ;Transplantation and Cellular Therapy. 2022 Jun 1
• Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
  Amneet Bajwa, Ying Huang, Rui Li, Nathan Denlinger, Jonathan Brammer, Sam Penza, Ayman Saad, Samantha Jaglowski, Adam S Kittai> ;Leukemia & Lymphoma. 2022 Jun 1
• 13 citations
  Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
  Deborah M Stephens, Ying Huang, Amy S Ruppert, Janek S Walker, Daniel Canfield, Casey B Cempre, Qiang Fu, Sharyn Baker, Boyu Hu, Harsh Shah, Renee Vadeboncoeur, Kerry ...> ;Clinical Cancer Research. 2022 Aug 2
• 4 citations
  Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.
  Pashna N Munshi, Yue Chen, Kwang W Ahn, Farrukh T Awan, Amanda Cashen, Geoffrey Shouse, Mazyar Shadman, Paul Shaughnessy, Joanna Zurko, Frederick L Locke, Aaron M Good...> ;Transplantation and Cellular Therapy. 2022 Aug 1
• 5 citations
  Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes.
  Malika Kapadia, Leslie Lehmann, Jeffery Auletta, Lisa Beatty, Neel Bhatt, Robyn Blacken, Kathy Demmel, Therese Dodd, Catherine Desmond, Taylor Fitch, Laura Flesch, Dav...> ;Transplantation and Cellular Therapy. 2022 May 1
• Join now to see all

Journal Articles

• A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation  
  Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen G, Jagasia M, Mayer S, Wood W, Green M, Hyun T, Inamoto Y, Storer B, Miklos D, Shulman H, Marti..., Clin Cancer Research, 1/15/2016
• Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors  
  Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Vachanova V, Bacher U, Dahi P, deLima M, D’Souza A, Fenske TS, Ganguly S, Kharfan-Dajaba MA, Prestidge TD, Sav..., J Clin Oncol, 1/6/2016
• Granulocyte colony-stimulating factor-mobilized allografts contain activated immune cell subsets associated with risk of acute and chronic graft-versus-host disease  
  Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O’Donnell L, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Be..., Biol Blood Marrow Transplant, 1/1/2016
• Endothelial chimerism in chronic sclerotic-type chronic graft-versus-host disease and GVHD-associated angiomatosis  
  Kaffenberger BH, Zhang E, Duncan JR, Jaglowski S, Klisovic RB, Devine SM, Wong HK, Gru AA, Br J Dermatol, 1/1/2016
• Allogeneic transplantation provides durabie remission in a subset of DLBCL patients relapsing after autologous transplantation  
  Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D’Souza A, Farooq U, Freytes C, Gangul..., Br J Haematology, 1/1/2016
• Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy  
  Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S, Bone Marrow Transplant, 1/1/2016
• Tocilizumab for steroid-refractory acute graft-versus-host disease  
  Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA, Leuk Lymphoma, 1/1/2016
• Atorvastatin for the prophylaxis of acute graft vs host disease (GVHD) in patients undergoing HLA-matched related donor hematopoietic stem cell transplantation (HSCT)  
  Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O’..., Biol Blood Marrow Transplant, 1/1/2016
• Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study  
  Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke..., Blood, 1/13/2015
• Hypermorphic mutation of phospholipase C gamma-2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation  
  Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC,..., Blood, 1/2/2015
• Lower dose of antithymocyte globulin (ATG) does not increase graft-versus-host disease (GVHD) in patients undergoing reduced-intensity conditioning (RIC) allogeneic he...  
  Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA, Leuk Lymphoma, 1/1/2015
• A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma  
  Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Pen..., Leuk Lymphoma, 1/1/2015
• Health related quality of life in patients that develop bronchiolitis obliterans syndrome following allogeneic stem cell transplantation  
  Amin E, Phillips G, Elder P, Jaglowski S, Devine S, Wood K, Bone Marrow Transplant, 1/1/2015
• A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory lymphoma  
  Maddocks K, Christian BA, Jaglowski SM, Flynn J, Jones J, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA, Blood, 1/1/2015
• Etiology of ibrutinib discontinuation and outcomes in patients with chronic lymphocytic leukemia  
  Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, ..., JAMA Oncol, 1/1/2015
• miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with ibrutinib  
  Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC, Leukemia, 1/1/2015
• Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia  
  Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hesler J, Grever MR, Im E, Zhou H Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC, Leukemia, 1/1/2015
• Impact of pretransplantation 18F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgki...  
  Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D’Souza A, Freytes C..., Biol Blood Marrow Transplant, 1/1/2015
• Externally validated predictive clinical model for untreated del(17p131) chronic lymphocytic leukemia patients  
  Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O’Brien S, Keating MJ, Muthusa..., Am J Hematol, 1/1/2015
• Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib  
  Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, LiDH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Loz..., N Engl J Med, 1/12/2014
• Graft-versus-Host disease: Why Haven’t We Made More Progress?  
  Jaglowski SM, Devine SM, Curr Opinion Hematol, 1/1/2014
• Transplant for CLL: still an option?  
  Jaglowski SM, Blood, 1/1/2014
• An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor  
  Haverkos B, McBride A, O’Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos L, Devine S, Jaglowski S, Bone Marrow Transplant, 1/1/2014
• Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease  
  El Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee ..., Biol Blood Marrow Transplant, 1/1/2014
• The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma  
  Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA, Bone Marrow Transplant, 1/1/2014
• Join now to see all

Abstracts/Posters

• A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
  Samantha Jaglowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Antithymocyte Globulin (ATG) 4.5 vs 6.0 mg/kg in Reduced Instnsity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)
  Issa H, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Jaglowski S, Devine SM, Efebera YA, ASBMT Annual Meeting, 1/1/2016
• Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand)as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation
  Jaglowski S, Waller EK, Kindwall-Keller TL, McCarty JM, Dugan M, Yellin M, Davis T, Devine SM, Biol Blood Marrow Transplant, 1/1/2016
• Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand)as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation
  Jaglowski S, Waller EK, Kindwall-Keller TL, McCarty JM, Dugan M, Yellin M, Davis T, Devine SM, ASBMT Annual Meeting, 1/1/2016
• Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts
  Rotta M, Wei L, Kitzler R, Bradbury H, Bingman A, Vasu S, Jaglowski S, Blum W, Klisovic R, Penza S, Andritsos LA, Efebera YA, Lozanski G, Devine SM, Biol Blood Marrow Transplant, 1/1/2016
• Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts
  Rotta M, Wei L, Kitzler R, Bradbury H, Bingman A, Vasu S, Jaglowski S, Blum W, Klisovic R, Penza S, Andritsos LA, Efebera YA, Lozanski G, Devine SM, ASBMT Annual Meeting, 1/1/2016
• Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid-Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
  Miklos D, Cutler C, Arora M, Waller E, Jagasia M, Nakamura R, Blazar B, Juretic M, Li Y, Dubovsky J, James D, Styles L, Jaglowski S, Bone Marrow Transplant, 1/1/2016
• Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid-Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
  Miklos D, Cutler C, Arora M, Waller E, Jagasia M, Nakamura R, Blazar B, Juretic M, Li Y, Dubovsky J, James D, Styles L, Jaglowski S, EBMT Annual Meeting, 1/1/2016
• Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem ...
  Miklos DB, Coutre S, O’Brien S, Byrd JC, Hillmen P, Brown JR, Dyer M, Mato AR, Keating M, Zhou C, Fardis M, Styles L, Jaglowski S, ASBMT Annual Meeting, 1/1/2015
• A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation
  Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Palmer J, Chen GL, Khera N, Mayer S, Jagasia MH, Wood WA, Martin PJ, Inamoto Y, Miklos DB, Lee SJ, Flowers MED, Biol Blood Marrow Transplant, 1/1/2015
• A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation
  Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Palmer J, Chen GL, Khera N, Mayer S, Jagasia MH, Wood WA, Martin PJ, Inamoto Y, Miklos DB, Lee SJ, Flowers MED, ASBMT Annual Meeting, 1/1/2015
• A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients w...
  Haverkos B, Cortright K, Andritsos LA, Blum W, Klisovic R, Vasu S, Goldenberg DM, Wegener W, Devine SM, Jaglowski S, Biol Blood Marrow Transplant, 1/1/2015
• A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients w...
  Haverkos B, Cortright K, Andritsos LA, Blum W, Klisovic R, Vasu S, Goldenberg DM, Wegener W, Devine SM, Jaglowski S, ASBMT Annual Meeting, 1/1/2015
• A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD)
  Miklos DB, Arora M, Cutler CS, Nakamura R, Juretic M, Li Y, Styles LA, James DF, Jaglowski SM, J Clin Oncol, 1/1/2015
• A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD)
  Miklos DB, Arora M, Cutler CS, Nakamura R, Juretic M, Li Y, Styles LA, James DF, Jaglowski SM, ASCO Annual Meeting, 1/1/2015
• Join now to see all

Lectures

• Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Tr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Stem Cell Transplantation for the General Internist 
  The Ohio State University, Columbus, OH - 1/9/2015
• A Phase Ib/II Multi-Center Study of Ibrutinib in Steroid Dependent/Refractory Chronic Graft-versus-Host Disease 
  Grapevine, TX - 1/25/2014
• Stem Cell Transplantation 
  The Ohio State University, Columbus, OH - 1/22/2014
• Graft-versus-Host Disease 
  The Ohio State University, Columbus, OH - 1/3/2014
• Ask the Expert: Bone Marrow Transplant 
  Columbus, OH - 1/14/2013
• Non-Hodgkin’s Lymphoma 
  The Ohio State University, Columbus, OH - 1/12/2013
• Project Cancer Education 
  Arthur G. James Cancer Hospital, Columbus, OH, 2009, 2010, 2011, 2012 - 1/22/2012
• Aggressive Lymphomas 
  The Ohio State University, Columbus, OH - 1/22/2012
• Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era: the CORAL Study 
  The Ohio State University, Columbus, OH - 1/5/2011
• Late Effects of Hematopoietic Stem Cell Transplant 
  The Ohio State University, Columbus, OH - 1/1/2011
• Lovenox Hurts 
  The Ohio State University College of Medicine and Public Health, Columbus, OH - 1/16/2009
• Join now to see all

Other

• The Effects of y-Tocopheryl Quinone on HeLa Cervical Carcinoma Cells (Senior thesis) 
  Jaglowski SM, The Ohio State University